Using her insight gained at the U.S. Department of Health and Human Services, Office of the General Counsel (HHS-OGC), Dawn Perez-Slavinski advises healthcare clients on complex regulatory issues implicated by day-to-day operations, healthcare transactions, and internal and government investigations. Her practice focuses on evaluating and mitigating legal risks and exposure that arise in the context of healthcare program participation, billing, and reimbursement requirements. As part of this work, Dawn also helps clients comply with government reporting and repayment obligations. In addition, Dawn assists clients in navigating emerging areas, such as regulatory waivers issued in the context of COVID-19, and eligibility and permitted uses for HHS’s Relief Fund payments.
Prior to joining Bass, Berry & Sims, Dawn was a program integrity attorney in the CMS Division of HHS-OGC. In this capacity, she helped CMS evaluate disclosures made under the Self-Referral Disclosure Protocol, review the legality of CMS regulations and guidance, and create safeguards to protect the financial integrity of the Medicare and Medicaid programs. In addition, Dawn counseled CMS’s Innovation Center on how to create financial protections and flexibilities for various alternative payment models, including waivers of federal fraud and abuse laws. Dawn also provided critical support to the HHS Office of Inspector General and the U.S. Department of Justice, and represented CMS, in False Claims Act investigations and litigation.
Prior to her experience at HHS-OGC, Dawn was an associate in the healthcare and corporate practice groups of a Virginia-based law firm. In this role, Dawn focused on administrative appeals of Medicare and Medicaid overpayment determinations, and HIPAA, managed care and licensure issues.
American Health Law Association (AHLA) — Regulation, Accreditation, and Payment Practice Group Leadership Development Program (2019-2020)
Virginia State Bar
Represented Addus HomeCare Corporation (Nasdaq: ADUS) in four strategic acquisitions and in its underwritten public offering of 2.3 million shares of common stock in 2019.